SCOR generates resilient results and confirms the Group’s capacity to absorb large shocks.
Availability of the documents that must be provided to the general shareholders' meeting.
Dem Risiko des falschen Umgangs mit genetischen Informationen, welches durch die Ausdehnung der Verbote auf diagnostische Gentests gesteigert wurde, sollte mit einem erhöhten Maß an Sorgfalt begegnet werden, insbesond
On Friday 6 March 2010, STOXX announced SCOR’s addition to its “EuroStoxx Select Dividend 30” index.
SCOR's 2009 results.
SCOR demonstrates its capacity to combine growth, profitability and solvency and records a net result of EUR 370 million.
SCOR demonstrates its capacity to combine growth, profitability and solvency and records a net result of EUR 370 million.
SCOR demonstrates its capacity to combine growth, profitability and solvency and records a net result of EUR 370 million
CMI Working Paper 43 is an exciting development as it is the first time that the CMI has published insured lives diagnosis rates – something the industry has been desperately seeking for the last decade.
As announced back in October 2009, Julien Carmona is appointed Group Chief Operating Officer as of 1 January, replacing Patrick Thourot who is retiring.